Turbine, a notable biological simulation company specializing in the creation of a platform for simulating human biology in silico, has recently disclosed a collaboration with AstraZeneca, a global biopharmaceutical company. The partnership will see Turbine employing its proprietary Simulated Cell™ platform to identify and understand mechanisms of resistance to therapy in hematological cancers. Specifically, the collaboration will focus on comprehending resistance mechanisms resulting from altered protein-protein interactions, with the ultimate goal of facilitating more personalized treatment regimens based on the molecular profiles of individual patients. While the financial terms of this collaboration have not been disclosed, the joint effort is anticipated to contribute to the development of enhanced and more enduring therapies for patients in need.

Szabolcs Nagy, Chief Executive Officer, and Co-Founder of Turbine, has highlighted the company's prior collaboration with AstraZeneca researchers in evaluating the platform's ability to identify mechanisms and potential biomarkers of response or resistance to personalized treatment combinations. Nagy expressed excitement about the expanded collaboration with AstraZeneca, emphasizing the opportunity to apply their technology to address new questions regarding molecular alterations that lead to drug resistance and potential strategies for overcoming them.

This collaboration builds upon a previous partnership between Turbine and AstraZeneca, where an earlier version of the Simulated Cell was utilized to predict combination synergy and identify biomarker candidates related to DNA Damage Repair mechanisms. The study, which assessed numerous drug combinations across various cancers, demonstrated the platform's ability to predict their effects without reliance on experimental data training. Simulations conducted as part of this earlier collaboration revealed potential mechanisms underlying the synergy between combinations of cancer treatments, offering insights into biomarkers of response and resistance that could be translated into clinical practice. The results of these studies, showcasing Turbine's platform matching predictivity while providing deeper insights into the biological complexity of response mechanisms, have been made publicly available on the bioRxiv preprint server and are currently under review for publication in a peer-reviewed journal.

Source: businesswire.com